PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMebutamate
Mebutamate
Dormate (mebutamate) is a small molecule pharmaceutical. Mebutamate was first approved as Dormate on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mebutamate
Tradename
Company
Number
Date
Products
DORMATEMedpointe Pharm HlcN-017374 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
2xl mega roll sanitizing wipes 2300 count megarollOTC monograph not final2022-11-29
2xl mega rolls sanitizing wipesC2002632024-12-06
bain de soleilOTC monograph final2023-09-08
cabliviBiologic Licensing Application2024-11-04
cellbn mega plusunapproved drug other2017-05-29
dr andrew weils for originsC2002632023-09-11
dr weils mega-defense advanced daily uv defender broad spectrum spf 45OTC monograph not final2021-07-14
dr. andrew weil for originsC2002632024-12-25
jba verestor mega fiber caffe latteunapproved drug other2024-11-11
jba verestor mega fiber powderunapproved drug other2024-11-11
Show 31 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N05: Psycholeptics
N05B: Anxiolytics
N05BC: Carbamate anxiolytics
N05BC04: Mebutamate
HCPCS
No data
Clinical
Clinical Trials
280 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.91179
Diabetes mellitusD003920EFO_0000400E08-E1311147
Insulin resistanceD007333EFO_0002614E88.8191135
Critical illnessD016638134
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.92114
Resistance trainingD055070134
Myofascial pain syndromesD009209EFO_1001054134
FibromyalgiaD005356EFO_0005687M79.1134
Lung diseasesD008171EFO_0003818J98.41113
Obstructive lung diseasesD008173213
Show 12 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SyndromeD013577279
Sleep initiation and maintenance disordersD007319F51.01145
Breast neoplasmsD001943EFO_0003869C50123
CarcinomaD002277C80.01213
AnemiaD000740EFO_0004272D64.91113
Cognitive dysfunctionD060825G31.84123
Esophageal neoplasmsD004938C1522
Hematologic neoplasmsD0193371112
MemoryD008568112
Blastic plasmacytoid dendritic cell neoplasmD000099067C86.411
Show 23 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients167
Type 2 diabetes mellitusD003924EFO_0001360E11145
DepressionD003863F33.9145
GliomaD005910EFO_0000520145
Depressive disorderD003866EFO_1002014F32.A145
Transcranial magnetic stimulationD050781112
GlioblastomaD005909EFO_0000515112
Fanconi anemiaD005199Orphanet_84D61.0311
Fanconi syndromeD00519811
Neuronal plasticityD00947311
Show 3 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ExerciseD015444EFO_000048388
Dental cariesD003731EFO_0003819K0288
OsteoarthritisD010003EFO_0002506M15-M1977
Covid-19D000086382U07.166
OverweightD050177E66.355
Postoperative painD010149G89.1855
Psychomotor agitationD01159544
AgingD000375GO_0007568R41.8144
Mental disordersD001523EFO_0000677F91.944
Hip osteoarthritisD015207EFO_1000786M1644
Show 232 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMebutamate
INNmebutamate
Description
Mebutamate (Capla, Dormate) is an anxiolytic and sedative drug with antihypertensive effects of the carbamate class. It has effects comparable to those of barbiturates such as secobarbital, but is only around 1/3 the potency of secobarbital as a sedative. Side effects include dizziness and headaches.
Classification
Small molecule
Drug class
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCC(C)C(C)(COC(N)=O)COC(N)=O
Identifiers
PDB
CAS-ID64-55-1
RxCUI
ChEMBL IDCHEMBL1200922
ChEBI ID
PubChem CID6151
DrugBank
UNII ID5H8F175RER (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 30,858 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,990 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use